Vaccine, Год журнала: 2024, Номер 45, С. 126615 - 126615
Опубликована: Дек. 25, 2024
Repeated COVID-19 booster vaccination was recommended in healthcare workers (HCWs) to maintain protection. We measured the relative vaccine effectiveness (rVE) of second dose compared first booster, against laboratory-confirmed SARS-CoV-2 infection HCWs.
Язык: Английский
GeroScience, Год журнала: 2024, Номер 46(3), С. 2879 - 2883
Опубликована: Янв. 10, 2024
Язык: Английский
Процитировано
19
bioRxiv (Cold Spring Harbor Laboratory), Год журнала: 2024, Номер unknown
Опубликована: Фев. 29, 2024
Neutralizing antibodies correlate with protection against SARS-CoV-2. Recent studies, however, show that binding antibody titers, in the absence of robust neutralizing activity, also from disease progression. Non-neutralizing cannot directly protect infection but may recruit effector cells thus contribute to clearance infected cells. Also, they often bind conserved epitopes across multiple variants. We characterized 42 human mAbs COVID-19 vaccinated individuals. Most these exhibited no activity
Язык: Английский
Процитировано
7
Cell Reports, Год журнала: 2024, Номер 43(11), С. 114922 - 114922
Опубликована: Ноя. 1, 2024
Neutralizing antibodies correlate with protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Recent studies, however, show that binding antibody titers, in the absence of robust neutralizing activity, also disease progression. Non-neutralizing cannot directly protect infection but may recruit effector cells and thus contribute to clearance infected cells. Additionally, they often bind conserved epitopes across multiple variants. Here, we characterize 42 human monoclonal (mAbs) from 2019 (COVID-19)-vaccinated individuals. Most these exhibit no activity vitro, several non-neutralizing provide lethal challenge SARS-CoV-2 different animal models. A subset those mAbs shows a clear dependence on Fc-mediated functions. We have determined structures three antibodies, two targeting receptor-binding domain one binds subdomain 1 region. Our data confirm real-world observation humans can be protective.
Язык: Английский
Процитировано
4
Enfermedades infecciosas y microbiologia clinica (English ed ), Год журнала: 2025, Номер 43(1), С. 36 - 46
Опубликована: Янв. 1, 2025
Despite high initial vaccination rates, Spain's current COVID-19 coverage in recommended groups does not meet WHO targets. For the upcoming season, challenges include revising age, updating risk groups, and unifying criteria with flu vaccine co-administration. European Commission's advance purchase agreements limit access to certain vaccines, need for vaccines effective against variants adds administrative complexities. recommendations should adapt these specific circumstances. Using predominant appropriate response duration is crucial protect at-risk populations. Enhancing training health education campaigns professionals general public, alongside utilizing tools simplify recommendations, can promote higher rates Spain. Addressing essential ensure adequate protection improve coverage, ultimately achieving better public outcomes face of evolving threats.
Язык: Английский
Процитировано
0
Influenza and Other Respiratory Viruses, Год журнала: 2025, Номер 19(1)
Опубликована: Янв. 1, 2025
ABSTRACT SARS‐CoV‐2, which originated in China late 2019, quickly fueled the global COVID‐19 pandemic, profoundly impacting health and economy worldwide. A series of vaccines, mostly based on full SARS‐CoV‐2 Spike protein, were rapidly developed, showing excellent humoral cellular responses high efficacy against both symptomatic infection severe disease. However, viral evolution waning neutralizing strongly challenged vaccine long term effectiveness, mainly infection, making necessary a strategy repeated updated booster shots. In this vaccination context, antibody repertoire diversification was evidenced, although immune imprinting after doses or reinfection also demonstrated identified as major determinant immunological to antigen exposures. Considering that small domain receptor binding (RBD), is target antibodies concentrates most mutations, following text aims provide insights into ongoing debate over best strategies for boosters. We address relevance developing new vaccines evolving RBD, thus focusing relevant antigenic sites variants. combination with immunofusing computerized approaches could minimize imprinting, therefore optimizing efficacy.
Язык: Английский
Процитировано
0
Journal of Infection and Public Health, Год журнала: 2025, Номер 18(6), С. 102746 - 102746
Опубликована: Март 12, 2025
Protection against severe course of SARS-CoV-2 infection after COVID-19 vaccination or was extensively studied. It is unknown whether this effect also translates into shortened duration mild infections. We assessed the symptoms depending on status and previous infections among individuals with a infection. For two post-pandemic winters (2022/2023 2023/2024), in total 13,615 participants German DigiHero study reported their from September to March. Via negative binomial regression adjusting for sociodemographic factors, we studied association (days bed) number vaccinations, prior infections, time since last vaccination/and noted no major differences vaccinations short (≤21 days symptoms). Per 6 months vaccination, symptom spent bed increased by 2 % 4 %. The risk long (>21 symptoms) higher (Odds Ratio: 1.98; 95 confidence interval [1.43; 2.76]), but not (OR: 0.98; CI [0.74; 1.33]). There indication reduced during A protective prolonged disease
Язык: Английский
Процитировано
0
Seminars in Respiratory and Critical Care Medicine, Год журнала: 2025, Номер unknown
Опубликована: Март 31, 2025
Abstract Whenever a new COVID-19 vaccination season starts, we must face challenges, including which vaccines to use, the update of high-risk groups be vaccinated, and especially type amount information communicated people in order promote vaccination. recommendations should fit these specific conditions. The use effective against predominant SARS-CoV-2 virus variants extent immune response (waning immunity) are key aspects try protect better populations. Updated currently swiftly available. However, number vaccinated with any additional booster dose is declining. Improved health training for care professionals, together tools make simpler recommendations, can encourage higher rates. Addressing challenges essential improve coverage ensure adequate protection evolving threats. has become constant presence our society. changes but neither endemic nor seasonal so far. Omicron variant prevailed nearly 2 years now several its subvariants like JN.1, KP.2, or XEC dominant ones. In this moving situation, main message same: safe effective. role current efforts mitigate severity disease reduce risk complications death, instead preventing most infections. New at different stages clinical research.
Язык: Английский
Процитировано
0
Medicina, Год журнала: 2024, Номер 60(3), С. 385 - 385
Опубликована: Фев. 25, 2024
While the World Health Organization (WHO) has de-escalated coronavirus disease 2019 (COVID-19) from a global health emergency, ongoing discussions persist as new viral variants. This article aimed to consolidate German recommendations and international research offer care providers (HCPs) comprehensive guide on COVID-19 boosters in 2024. The review outlines key Robert Koch Institute. HCPs should receive at least 12 months after their last vaccination or infection, contingent prevalent variant(s) region. However, excessive doses and/or frequent boosters, especially with mRNA vaccines, may lead immune imprinting, T-cell exhaustion, immunoglobulin (Ig) switching. Notably, this highlights significance of Ig, particularly IgA IgG subclasses, influencing infection risk progression. Furthermore, it explores implications vaccine technology potential adverse effects related dosing. In conclusion, provides analysis for HCPs, synthesising current recommendations, scientific debates, considerations optimising protection against SARS-CoV-2 evolving landscape post-pandemic era.
Язык: Английский
Процитировано
2
Frontiers in Public Health, Год журнала: 2024, Номер 12
Опубликована: Авг. 26, 2024
Hybrid immunity (a combination of natural and vaccine-induced immunity) provides additional immune protection against the coronavirus disease 2019 (COVID-19) reinfection. Today, people are commonly infected vaccinated; hence, hybrid is norm. However, mitigation risk Omicron variant reinfection by durability its remain uncertain. This meta-analysis aims to explore mitigate protective provide a new evidence-based basis for development optimization immunization strategies improve public's awareness participation in COVID-19 vaccination, especially vulnerable at-risk populations.
Язык: Английский
Процитировано
1
Eurosurveillance, Год журнала: 2024, Номер 29(35)
Опубликована: Авг. 29, 2024
BackgroundCOVID-19 remains a major infectious disease with substantial implications for individual and public health including the risk of post-infection syndrome, long COVID. The continuous changes in dominant variants SARS-CoV-2 necessitate careful study effect preventative strategies.AimWe aimed to estimate effectiveness post-vaccination, hybrid immunity against severe cases requiring oxygen support caused by infections BA1/2 BA4/5+, COVID infected population their over time.MethodsWe used Cox regression analysis time-varying covariates calendar time logistic applied national-level data from Czechia December 2021 until August 2023.ResultsRecently boosted vaccination, provide significant protection course COVID-19, while unboosted vaccination more than 10 months ago has negligible protective effect. post-vaccination or BA4/5+ variants, especially based on original vaccine types, appears wane rapidly compared immunity. Once infected, however, previous plays only small role COVID.ConclusionVaccination an effective measure COVID-19 but its wanes thus highlighting importance booster doses. vaccines may have development
Язык: Английский
Процитировано
1